Chemical APIs refer to APIs used in the production of various preparations, and are active ingredients in
preparations.
According to the China Chemical and Pharmaceutical Industry Association, the total operating income of China's chemical API industry reached 426.
5 billion yuan in 2021, and it is expected that the operating income of China's chemical API industry will reach 473.
6 billion yuan in 2023.
Since the beginning of the new year, the domestic pharmaceutical company's API industry has continued to provide news, including product approval, project production, etc
.
At the same time, some of the API drugs that have recently set off a rush of buying have attracted the attention of investors, and in recent days, many pharmaceutical companies, including Rundu Co.
, Ltd.
and Yiming Pharmaceutical, have responded to questions about relevant API projects that investors are concerned about on the interactive platform
.
Yiming Pharmaceutical said on the interactive platform on January 4 that the montmorillonite powder (Beiyiping) produced by the company was the first batch to pass the consistency evaluation
in China in June 2018.
Up to now, the company has passed the drug registration application of CDE montmorillonite API and completed the application for the new quality standard of montmorillonite scatter, which clearly indicates in the new testing standard that "ashling should not be detected", which is stricter than the current "Pharmacopoeia of the People's Republic of China" (2020 version
).
The company said it would adopt new standards as soon as possible to bring higher quality montmorillonite to market
.
The company's recent sales orders have increased, and the company now has sufficient production capacity to meet sales demand
.
Montmorillonite is an antidiarrheal drug, which has recently been rushed to buy and has become another drug
that is out of stock after antipyretic drugs such as ibuprofen and acetaminophen.
In this context, its related manufacturing enterprises, including API companies, have attracted the attention
of investors.
Hengdi Pharmaceutical said on the investor interactive platform on January 4 that the company's cardiovascular APIs include torasemide and milrinone, and cardiovascular preparations include torasemide tablets
.
Ibuprofen, which set off a rush to buy at the end of 2022, has also cooled down as relevant departments call on citizens not to blindly stock up on drugs and major pharmaceutical companies accelerate production
.
However, some manufacturers still have investors' attention
before they are put into production.
For example, Rundu Co.
, Ltd.
recently replied to investors on the interactive platform that the company's ibuprofen API passed the review and approval, indicating that the API meets the relevant Chinese drug review technical standards and has been approved for use
in domestic marketing preparations.
However, products are affected by factors such as GMP compliance inspection progress, national policies, and changes in the market environment, and there are uncertainties
in production and sales time and specific sales conditions.
In addition, the production progress of APIs of some pharmaceutical companies has also attracted the attention
of investors.
For example, Changshan Pharmaceutical said on the investor interactive platform on January 4 that the company will adhere to the established development strategy, expand API production capacity and export business scale, and the 35-ton heparin API project will accelerate follow-up work, strive to officially put into production as soon as possible, and gradually release production capacity
according to market demand and the company's actual situation.
It is understood that the 35-ton heparin series API product project is a key project of Changshan Pharmaceutical in 2022, and it was originally planned to be put into production
before the end of 2022.
Changshan Pharmaceutical mentioned at the previous performance briefing: "After the completion of the 35-ton heparin API expansion project, it can greatly increase the production capacity of the company's heparin APIs, especially low molecular weight heparin APIs, which will positively promote the expansion of the company's export business
.
" ”
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
